5-BrdU-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemE5-BrdUCat.No.:HY-15910CASNo.:59-14-3分?式:C?H??BrN?O?分?量:307.1作?靶點:NucleosideAntimetabolite/Analog作?通路:CellCycle/DNADamage儲存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfromlight)溶解性數(shù)據(jù)體外實驗DMSO:≥41mg/mL(133.51mM)掃描?維碼，H2O:33.33mg/mL(108.53mM;Needultrasonic)運?溶解?案計算器*"≥"meanssoluble,butsaturationunknown.獲得適合您實驗體系的溶解?案MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.2563mL16.2813mL32.5627mL5mM0.6513mL3.2563mL6.5125mL10mM0.3256mL1.6281mL3.2563mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存?式和期限。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶1.請依序添加每種溶劑：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.08mg/mL(6.77mM);Clearsolution此?案可獲得≥2.08mg/mL(6.77mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL20.8mg/mL的澄DMSO儲備液加到400μLPEG300中，混合均勻；向上述2.體系中加?50μLTween-80，混合均勻；然后繼續(xù)加?450μL?理鹽?定容?1mL。請依序添加每種溶劑：10%DMSO90%(20%SBE-β-CDinsaline)1/3www.MedChemEwww.MedChemESolubility:≥2.08mg/mL(6.77mM);Clearsolution此?案可獲得≥2.08mg/mL(6.77mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL20.8mg/mL的澄DMSO儲備液加到900μL20%的SBE-β-CD?理鹽??溶3.液中，混合均勻。請依序添加每種溶劑：10%DMSO90%cornoilSolubility:≥2.08mg/mL(6.77mM);Clearsolution此?案可獲得≥2.08mg/mL(6.77mM，飽和度未知)的澄溶液，此?案不適?于實驗周期在半個?以上的實驗。4.以1mL?作液為例，取100μL20.8mg/mL的澄請依序添加每種溶劑：PBSDMSO儲備液加到900μL??油中，混合均勻。Solubility:16.25mg/mL(52.91mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性5-BrdU(BrdU)?種核苷類似物，可與胸苷競爭摻?DNA。5-BrdU通常?于檢測增殖細胞。體外研究Bromodeoxyuridineinducesaprogressive,dose-responsivesuppressionofcancercelllineandcancerstemcellpopulationexpansionRG2ratgliomacells.InH9cellsandBJfibroblasts,bromodeoxyuridinealtersthecellcycleprofile[1].BrdUisstablyintegratedintotheDNA,andthuscanbeusedinassessmentofcellproliferationandothercellprocession[2].體內(nèi)研究Bromodeoxyuridine(300mg/kg,i.p.or0.8mg/mL,p.o.)significantlyslowstumorprogressioninratgliomaRG2tumormodel[1].PROTOCOLCellAssay[1]Culturesareinitiallyplatedat2000cells/cm2andarequantifiedwithaZ2CoulterCounter.RG2ratgliomacellsaretreatedoncewith0,1,10,or50μMBrdUfor24hours,andcumulativegrowthcurvesareobtainedover18days.Controlandtreatedcellsarequantifiedandreplatedatequaldensitiesondays5,12,and18aftertreatment.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?CellRes.2020Sep;30(9):732-744.?CellRes.2019Jan;29(1):23-41.?CellRep.2021Apr13;35(2):108952.?CellDeathDis.2020Apr6;11(4):219.?JCellPhysiol.2020Jul;235(7-8):5764-5776.Seemorecustomervalidationsonwww.MedChemEREFERENCES2/3www.MedChemEwww.MedChemE[1].LevkoffLH,etal.Bromodeoxyuridineinhibitscancercellproliferationinvitroandinvivo.Neoplasia.2008Aug;10(8):804-16.[2].RothaeuslerK,etal.Assessmentofcellproliferationby5-bromodeoxyuridine(BrdU)labelingformulticolorflowcytometry.CurrProtocCytom.2007Apr;Chapter7:Unit7.31McePdfHeight關(guān)注MCE中國公眾號，

獲取前沿資訊、最新活動和

實?科研?具MedChemExpress(MCE)只為有資質(zhì)的科研機構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報的?途提供醫(yī)藥研發(fā)服務(wù)，

不為